Exploration | PSMA-Targeting Macrophage Membrane-Coated Nanoparticles for Precision Diagnosis and Combination Therapy of Prostate Cancer

This study integrates cell membrane camouflage with genetic engineering-based targeting strategies, offering an innovative platform for precise drug delivery and immune regulation in prostate cancer, providing significant insights for the design of combined targeted and immunotherapeutic approaches.

 

Literature Overview

The article titled “PSMA-Targeting Macrophage Membrane-Coated Nanoparticles for Precision Diagnosis and Combination Therapy of Prostate Cancer,” published in the journal Exploration, systematically investigates the application of macrophage membrane-coated nanoparticles in targeted imaging and combination therapy for prostate cancer. The authors developed a nano-platform (P-MMCNPs) comprising a macrophage membrane stably expressing an anti-PSMA single-chain antibody fragment (scFv, gy-1), achieving dual functionality of immune evasion and tumor-specific recognition. By integrating a Fe₃O₄@Au nanocore, the platform gains multimodal imaging and photothermal therapy capabilities, and is loaded with the cytotoxic drug DM1 to form a multifunctional therapeutic system. The study not only validates its high targeting efficiency and antitumor efficacy in both primary and metastatic prostate cancer models but also reveals an intrinsic immunomodulatory role of the macrophage membrane through neutralization of pro-tumor cytokines, thereby expanding the potential of nanocarriers in modulating the tumor microenvironment.

Background Knowledge

Prostate cancer (PCa) is one of the most common malignancies in men, with advanced cases frequently progressing to hormone-refractory states associated with extremely poor prognosis. Current clinical management primarily relies on androgen deprivation and chemotherapy, yet drug resistance often develops, highlighting an urgent need for more precise therapeutic strategies. Prostate-Specific Membrane Antigen (PSMA), a type II transmembrane protein highly expressed in high-grade, metastatic, and hormone-resistant prostate cancers, has emerged as an ideal molecular target. However, conventional nanodrugs are often rapidly cleared by the immune system due to their foreign nature and weak targeting, resulting in insufficient tumor accumulation. Although various cell membrane coating strategies (e.g., erythrocytes, platelets) have been used to improve biocompatibility, macrophage membranes offer superior advantages due to their inherent immune evasion and tumor-tropic properties. Nevertheless, their targeting relies on chemokine gradients and lacks specific recognition capability. Therefore, enhancing specific PSMA recognition while preserving the advantages of macrophage membranes represents a key challenge in improving targeting efficiency. This study elegantly addresses this challenge by genetically engineering macrophage membranes to express anti-PSMA scFv (gy-1) transmembranely, achieving a synergistic design of “bionic camouflage + active targeting.”

 

 

Research Methods and Experiments

The authors employed genetic engineering to construct Raw264.7gy-1-EGFP cells that stably express the PSMA-targeting scFv (gy-1) fused with EGFP. The cell membranes were then extracted and coated onto Fe₃O₄@Au nanoparticles (FeAuNPs) to form P-MMCNPs. The core–shell structure and stability were confirmed using transmission electron microscopy and dynamic light scattering. In vitro experiments using PC3PSMA+ and PC3PSMA− cell lines demonstrated, via flow cytometry and confocal imaging, that P-MMCNPs specifically bind and internalize into PSMA+ cells, a process blockable by anti-PSMA antibodies, thereby confirming the role of gy-1 in mediating targeting. In vivo biodistribution studies using ICG labeling, combined with fluorescence imaging, CT, and MRI, showed that P-MMCNPs significantly accumulate in both primary and bone-metastatic prostate cancer models, with a prolonged half-life of up to 10 hours, outperforming non-targeted control groups.

Key Conclusions and Perspectives

• A macrophage membrane-coated nanoparticle (P-MMCNPs) was successfully engineered to stably express anti-PSMA scFv, combining immune evasion with specific targeting, thus providing a reusable platform strategy for future nanodrug design
• P-MMCNPs@DM1 exhibit specific cytotoxicity against PSMA+ cells, and when combined with photothermal therapy, demonstrate synergistic tumor-killing effects, highlighting its significant advantages in combination therapy
• Animal experiments confirm that P-MMCNPs@DM1 combined with PTT significantly suppress tumor growth in both primary and bone-metastatic prostate cancer models, with no significant systemic toxicity observed, supporting its potential as a safe and effective therapeutic strategy
• Notably, even the drug-free P-MMCNPs themselves inhibit tumor growth by neutralizing pro-tumor cytokines (e.g., TGF-β, IL-4, IL-10) via the macrophage membrane, reprogramming tumor-associated macrophages from the M2 to M1 phenotype, revealing an intrinsic immunomodulatory function independent of drug loading

Research Significance and Prospects

This study presents a multifunctional platform integrating diagnosis and therapy for precision treatment of prostate cancer. The “active targeting + immune camouflage” design strategy can be widely applied to other PSMA-overexpressing tumors, such as certain types of renal cell carcinoma and glioblastoma. More importantly, the cytokine-neutralizing capacity of macrophage membranes offers a novel approach to modulating immunosuppressive tumor microenvironments, potentially enhancing the efficacy of immune checkpoint inhibitors. Future studies may explore the application of P-MMCNPs in combination with CAR-T or antibody-based therapies to further amplify antitumor immune responses.

 

 

Conclusion

The P-MMCNPs platform developed in this study represents a significant advancement in targeted prostate cancer therapy. By genetically engineering macrophage membranes to achieve high-affinity recognition of PSMA, it not only overcomes the poor targeting of conventional nanoparticles but also leverages the natural properties of cell membranes for prolonged circulation and immune evasion. The Fe₃O₄@Au core enables multimodal imaging and photothermal therapy, while DM1 loading allows for synergistic chemotherapy, forming an integrated “theranostic” system. More profoundly, the platform itself possesses immunomodulatory functions by neutralizing pro-tumor cytokines and reshaping the tumor microenvironment, offering a novel strategy to overcome immunosuppression. From bench to bedside, this technology holds promise for delivering more precise, low-toxicity, and efficient personalized therapies for prostate cancer patients, particularly those with refractory or metastatic disease. Furthermore, the modular design of this platform can be extended to other targets, driving nanomedicine toward multifunctional and intelligent development, potentially becoming a cornerstone of future comprehensive cancer therapies.

 

Keying Zhang, Bo Gao, Jingwei Wang, Huijie Bian, and Weijun Qin. PSMA‐Targeting Macrophage Membrane‐Coated Nanoparticles for Precision Diagnosis and Combination Therapy of Prostate Cancer. Exploration.